Published in final edited form as:

Am J Cardiol. 2018 January 15; 121(2): 182–187. doi:10.1016/j.amjcard.2017.10.010.

Risk of Cardiac Events Associated with Antidepressant Therapy in Patients with Long QT Syndrome

Meng Weng, MS^{a,b}, Barbara Szepletowska, MD, PhD^a, Bronislava Polonsky, MS^a, Scott McNitt, MS^a, Arthur J. Moss, MD^a, Wojciech Zareba, MD, PhD^a, and David S. Auerbach, PhD^{c,d}

^aDepartment of Medicine-Heart Research Follow-up Program

^bDepartment of Public Health Sciences

^cDepartment of Medicine-Aab Cardiovascular Research Institute

^dDepartment of Pharmacology & Physiology University of Rochester Medical Center, Rochester, NY USA

Abstract

Long QT Syndrome (LQTS) patients are at a high risk for cardiac events. Many LQTS patients are treated with antidepressant drugs (ADs). We investigated the LQTS genotype specific risk of recurrent cardiac arrhythmic events (CAEs) associated with ADs therapy. The study included 59 LQT1 and 72 LQT2 patients from the Rochester-based LQTS Registry with QT_c prolongation and a history of AD therapy. Using multivariate Anderson-Gill models we estimated the LQTS genotype specific risk of recurrent CAEs (ventricular tachyarrhythmias, aborted cardiac arrest, or sudden cardiac death) associated with time-dependent ADs. Specifically, we examined the risk associated with all ADs, SSRIs, and ADs classified on the CredibleMeds list (www.CredibleMeds.org) as “Conditional” or “Known risk of Torsades de pointe (TdP)”. After adjusting for baseline QT_c, sex, and time-dependent beta blocker usage, there was an increased risk of recurrent CAEs associated with ADs in LQT1 patients (HR=3.00, 95%CI: 1.55–5.84, p=0.001), but not in LQT2 patients (HR=1.05, 95%CI: 0.56–1.99, p=0.872; LQT1 vs. LQT2 interaction, p<0.001). Similarly, LQT1 patients who were on SSRIs or ADs with “Known risk of TdP” had a higher risk of recurrent CAEs than those off all ADs, whereas there was no association in LQT2 patients. ADs with “Conditional risk of TdP” were not associated with the risk of recurrent CAEs in any of the groups. In conclusion, the risk of recurrent CAEs associated with time-dependent ADs is higher in LQT1 patients, but not in LQT2 patients. Results suggest a LQTS genotype-specific effect of ADs on the risk of arrhythmic events.

Address for correspondence: David S. Auerbach PhD., Department of Medicine, Aab Cardiovascular Research Institute, University of Rochester Medical Center, 601 Elmwood Ave, Box CVRI, Rochester, NY 14642. Phone: (585) 276-3018, Fax: (585) 276-1530, david_auerbach@urmc.rochester.edu.

Disclosures: None

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

Antidepressant Drug; Long QT Syndrome; Cardiac Arrhythmia; Sudden Cardiac Death; Depression

Introduction

Long QT Syndrome (LQTS) is a genetic disease due to mutations in genes encoding cardiac ion channels (or interacting) proteins^{1,2}. LQT1 and LQT2 are due to loss-of-function mutations in *KCNQ1* (LQT1) and *KCNH2* (LQT2) genes that encode cardiac slow and rapid delayed rectifier potassium channels, respectively³. These mutations lead to corrected QT (QT_c) prolongation on the cardiac electrocardiogram (ECG), and a higher risk of ventricular arrhythmias and sudden cardiac death (SCD)³. The disease manifestations may raise psychological burdens, such as depression^{4,5}, and many LQTS patients are treated with antidepressants (ADs)⁶. Many studies investigating the pro-arrhythmic effect of ADs used QT duration as the endpoint^{7,8}. However, QT prolongation is not a perfect surrogate for ventricular arrhythmias^{9,10}. Case reports^{11,12} and epidemiological studies^{13–18} with a clinical endpoint yielded mixed results whether ADs are associated with a higher risk of ventricular arrhythmias and SCD. Since LQTS patients are at an increased risk of ventricular arrhythmias, ADs use in this clinical population requires careful evaluation. The present study evaluated the LQTS genotype specific risk of recurrent cardiac arrhythmias associated with AD use.

Methods

The Rochester-based LQTS Registry includes detailed clinical, pharmacologic, and genetic information about LQTS probands and their affected and unaffected family members¹⁹. A 12 lead ECG was obtained at enrollment. QT_c duration was calculated using the Bazett's formula. The present study consisted of 59 LQT1 and 72 LQT2 patients with QT_c prolongation (male QT_c>450ms, female QT_c>470ms) and a history of AD use (eTable 1). All patients had only one mutant LQTS gene. The LQTS Registry is approved by the University of Rochester Research Subject Review Board (RSRB00025305). HIPAA requirements for accounting for disclosure, consent, and withdrawal of consent were followed. There was no race/ethnicity or sex restriction for inclusion.

The primary endpoint was cardiac arrhythmic events (CAEs). This was a composite endpoint of recurrent ventricular tachyarrhythmia (sustained ventricular tachycardia, Torsades de pointe [TdP], and ventricular fibrillation), aborted cardiac arrest (ACA), and SCD. Multiple sources were used to ascertain the endpoint. For probands, ventricular tachyarrhythmia and ACA were collected from both patients' self-reports and physicians' reports. For family members, ventricular tachyarrhythmias and ACA were first assessed by direct contact with patients or relatives and then by medical record review of self-reported cardiac events. Implantable cardiac defibrillator (ICD) interrogations were obtained from patients in the LQTS ICD Registry. All SCDs were adjudicated by LQTS investigators based on medical records and descriptions surrounding death.

AD and beta blocker use, drug name, and dates of start/discontinuation of drugs were collected from enrollment and annual follow-up questionnaires from patients and physicians. We examined the risk of recurrent CAEs associated with overall AD use, as well as the most commonly used AD group, selective serotonin reuptake inhibitor (SSRIs). Furthermore, ADs were classified according to the CredibleMeds QTDrug list classification of the risk of TdP [dataset]²⁰. The risk of TdP was assigned based on multiple sources of evidence (e.g. FDA's Adverse Event Reporting System, case reports of TdP, studies of QT prolongation, and laboratory studies of relevant pharmacologic action, etc.)²¹. Drugs were classified as: (1) not on the CredibleMeds QTDrug list; (2) Conditional risk of TdP (these drugs prolong QT and have a risk of developing TdP but only under certain known conditions such as overdose or drug-drug interaction); (3) Possible risk of TdP (these drugs can cause QT prolongation but there is insufficient evidence that the drugs, when used as directed in labeling, have a risk of causing TdP); and (4) Known risk of TdP (these drugs prolong QT intervals and have a risk of TdP when used as directed in labeling)²¹.

Comparisons of clinical characteristics between LQT1 and LQT2 patients were performed by Chi-square test for categorical variables and two-sample t-test or Mann-Whitney U test (for skewed distributions) for continuous variables. Incidence rates of recurrent CAEs were calculated as the number of events per 100 person-years.

We performed Andersen-Gill models²² with time-dependent AD use (a patient's status of AD use could switch between on and off ADs over time) to assess the association of on vs. off ADs with the risk of recurrent CAEs. Follow-up was from birth to (1) last contact, (2) death due to reasons other than sudden cardiac death, (3) March 2016, or (4) sudden cardiac death or 10th CAEs (97% of all patients developed 10 ventricular arrhythmic events), whichever occurred first. To estimate the hazard ratios (HRs) of recurrent CAEs associated with ADs by LQTS genotype, we fitted a model including time-dependent ADs, LQTS genotype (LQT1 vs. LQT2), and an interaction term of these two variables. As many LQTS patients were prescribed SSRIs, we also assessed the risk of recurrent CAEs associated with SSRIs in LQT1 and LQT2 patients separately. Briefly, SSRIs was analyzed as a time-dependent categorical variable with four mutually exclusive groups: on SSRIs only, on other ADs only, on SSRIs and other ADs simultaneously, and off all ADs. We presented the HR of CAEs associated with on SSRIs only vs. off all ADs.

Next, we estimated the HR of recurrent CAEs associated with ADs in each class on the CredibleMeds list. We analyzed ADs as a time-dependent categorical variable with five levels. At any given time point, patients were classified into five mutually exclusive groups: **1)** patients on ADs that are not on the CredibleMeds list, **2)** patients on ADs with "Conditional risk of TdP", **3)** patients on ADs with "Possible risk of TdP", **4)** patients on ADs with "Known risk of TdP", and **5)** patients off all ADs (reference group). If a patient was on more than one class of ADs simultaneously, the patient was classified in the AD group with the highest risk level (known>possible>conditional>not on the list). To further estimate the effect of the most commonly used drug in the "Known risk of TdP" and SSRI group (Citalopram), we compared the risk of recurrent CAEs between patients on Citalopram to those off all ADs, in a similar way as described above (with six mutually exclusive groups: on Citalopram, on other ADs with "Known risk of TdP", on ADs with

“Possible risk of TdP”, on ADs with “Conditional risk of TdP”, on ADs not on the list, and off all ADs).

Using SAS software version 9.4 (SAS Institute, North Carolina), all analyses were stratified by sex, and adjusted for baseline QT_c duration and time-dependent beta blocker therapy. Significance (two-tailed tests) was defined as $p < 0.05$.

Results

Table 1 lists the clinical and demographic characteristics of the study population. There was no difference in follow-up and total time on any ADs, SSRIs, and ADs in each CredibleMeds risk of TdP classes between LQT1 and LQT2 patients. Baseline QT_c was similar between the two groups. There were 53 CAEs in 59 LQT1 patients during a mean follow-up of 53 ± 20 years, and 91 CAEs in 72 LQT2 patients during a mean follow-up of 48 ± 17 years. The percentage of patients who developed CAEs during follow-up was higher in LQT2 than in LQT1 patients (54% vs. 25%).

In both groups, patients had a higher incidence rate of CAEs when on vs. off ADs (Figure 1). LQT1 patients had a greater difference in the rate of CAEs on vs. off ADs (5.73 vs. 1.20 CAEs per 100 person years) compared to LQT2 patients (3.58 vs. 2.53 CAEs per 100 person-years). As is shown in Figure 2, after stratifying for sex, and adjusting for baseline QT_c and time-dependent beta-blocker therapy, there was an increased risk of recurrent CAEs when LQT1, but not LQT2, patients were on ADs (LQT1 vs. LQT2 interaction, $p < 0.001$.)

Similar to the results of overall AD use, both groups had higher rates of CAEs when on SSRIs compared to off all ADs (Figure 1). LQT1 patients had a greater difference in the rate of CAEs while on SSRIs vs. off all ADs compared to LQT2 patients. After adjusting for the same covariates as above, we observed similar LQTS genotype-specific effects of SSRIs on the risk of recurrent CAEs. LQT1, but not LQT2, patients were at an increased risk of recurrent CAEs on SSRIs vs. off all ADs (Figure 2).

As ADs with “Possible risk of TdP” and ADs not on the CredibleMeds list had 0 CAEs in many groups, rates of recurrent CAEs and HR estimates are not presented for these two groups. As shown in Figure 1, LQT1 patients had a higher rate of CAEs while on ADs with “Known risk of TdP” vs. when off all ADs, whereas LQT2 patients had a lower rate of CAEs while on ADs with “Known risk of TdP” vs. off all ADs.

Consistent with findings of overall ADs and SSRIs, the LQTS genotype-specific effect on the risk of CAEs was also observed for ADs with “Known risk of TdP.” LQT1 patients on ADs with “Known risk of TdP” had a higher risk of recurrent CAEs compared to those off all ADs. By contrast, in LQT2 patients the risk did not differ significantly when on ADs with “Known risk of TdP” vs. off all ADs. ADs with “Conditional risk of TdP” were not associated with a change in the risk of recurrent CAEs in any group. Furthermore, in LQT1 patients we examined the most commonly used AD in the “Known risk of TdP” group, Citalopram (17 patients reported a history of Citalopram usage), which is a SSRI. LQT1 patients on Citalopram were at an increased risk of recurrent CAEs compared to those off all

ADs (HR=6.79, 95% CI 3.18–14.51, $p<0.001$). Due to limited number of LQT2 patients on Citalopram, we were unable to compute the HR for Citalopram in LQT2 patients.

Discussion

This study provides insights into the LQTS genotype specific effect of ADs on the risk of recurrent CAEs. We observed an increased risk of recurrent CAEs associated with overall AD use, SSRIs, and ADs with “Known risk of TdP” in LQT1, but not in LQT2 patients.

Findings from prior epidemiologic studies investigating the association between ADs and the risk of cardiac events are inconsistent^{13,14,16,17}. These studies used administrative databases and included diverse clinical populations. A study using a case-time-control design demonstrated an increased risk of out-of-hospital cardiac arrest associated with ADs, specifically SSRIs and tricyclic antidepressants (TCAs)¹³. The increased risk associated with SSRIs was primarily driven by Citalopram¹³. In line with these results, we found an increased risk of recurrent CAEs associated with overall ADs use, SSRIs, and Citalopram vs. off all ADs in the LQT1 group. Several other studies compared Citalopram to a specific antidepressant. In a large Canada cohort, Citalopram was associated with a higher risk of cardiac events within 90 days of Citalopram prescription, compared to Paroxetine or Sertaline¹⁸. By contrast, two large studies of Medicaid enrollees reported no change in the risk of sudden cardiac death or ventricular arrhythmias associated with Citalopram, compared to reference antidepressants (Fluoxetine, Paroxetine, or Sertraline)^{14,17}.

Our finding of ADs classified on the CredibleMeds list as “Known risk of TdP” is consistent with a Swedish case-control study of people 65 years and older, although for a different endpoint. This Swedish study reported a higher all-cause mortality associated with both ADs with “Known risk of TdP” and ADs with “Conditional risk of TdP”²³.

It should be noted that different from previous studies that used large administrative databases and included diverse clinical populations, our study focused on LQTS patients from the Rochester-based LQTS Registry. While administrative databases provide very large sample size, they are prone to non-differential outcome misclassification²⁴. Ventricular arrhythmias may be fatal and thus not identified if they occur outside hospital settings^{17,24}. In our study, SCDs was assessed by direct contact with relatives or friends of the deceased and all cases were adjudicated by LQTS investigators based on a description of the circumstances around death and medical records. Moreover, 53% of our study population had an ICD implanted. ICD interrogation provided ECG recordings of arrhythmic events that occurred outside the hospital. Thus, our study likely captured arrhythmic events more accurately than studies using administrative datasets.

QT prolongation via blockade of cardiac rapid delayed rectifier potassium current (I_{Kr}) is the primary proposed pro-arrhythmic mechanism for ADs^{7,8,25–28}. Some ADs have other adverse cardiovascular effects such as increased heart rate, increased sympathetic activity, decreased heart rate variability, and cardiac conduction delays^{28,29}. To explore potential mechanisms we compared ECG measures (heart rate, QT_c , and QRS durations) in patients with ECG recordings both on and off ADs. In both LQT1 and LQT2 patients, we did not

observe significant difference in these ECG measures while on vs. off ADs (eTable 2). These ECG results are only preliminary due to limited sample size and uncontrolled confounding (e.g. age, ECG readers, and medications at multiple ECG recordings per patient) and need to be examined in a larger prospective cohort with more rigorous control for confounders.

The mechanisms for the LQTS genotype-specific effect are unclear. We propose two potential mechanisms. First, LQT2 mutations in *KCNH2*, particularly those in the pore-S6 region, which has been suggested as the binding region for hERG blockers^{30,31}, may lead to the lack of target/binding sites for ADs to bind and exert I_{Kr} blocking effects. Therefore, LQT2 patients may be unaffected by the pro-arrhythmic effect of ADs. While we were not powered to perform multivariable analysis by mutation location, exploratory descriptive analyses suggested patients with LQT2 S5-pore-S6 domain mutations (n=18) had a lower rate of recurrent CAEs when on vs. off ADs (eFigure 1). These results indicate LQT2-pore mutations may alter the ability of ADs to exert I_{Kr} blocking effects. Our second proposed mechanism is increased sympathetic activity associated with some ADs. Previous studies suggested that TCAs and SNRIs were associated with increased sympathetic activity²⁹, which is an established trigger for arrhythmias in LQT1 patients³². While emotion and stress are triggers for arrhythmias in LQT2 patients, lethal events arise under many conditions that are not associated with increased sympathetic tone³³. It is also possible that both mechanisms operate simultaneously.

Our study has limitations that need to be considered. Except for Citalopram, our limited sample size did not allow us to thoroughly examine the risk of CAEs associated with specific ADs. While the use of ADs and SSRIs were associated with an increased risk of CAEs in LQT1 patients, it does not imply that all ADs and all SSRIs are associated with an increased risk of CAEs in LQT1 patients. Future prospective studies in a large cohort of LQTS patients are needed to confirm these results, and rigorously examine the risk of CAEs associated with specific ADs.

There is an increase in the risk of recurrent CAEs associated with overall AD use, SSRIs, and ADs with “known risk of TdP”, such as Citalopram, in LQT1 patients, but not in LQT2 patients. Results from the study establish the basis for future studies to investigate the mechanisms for this LQTS genotype-specific effect of ADs. It is important to consider genotype when prescribing ADs to LQTS patients.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial Support

The project was supported by University of Rochester CTSA Career Development award (NIH-NCATS KL2TR000095, DSA, Bethesda, MD, USA) and National Institutes of Health (5U01NS090405-03, DSA, HL-33843, AJM; HL-51618, AJM; & HL-123483, AJM, Bethesda, MD, USA), with no involvement in the study design, analyses, or interpretation.

Acknowledgements & Funding:

The project was supported by University of Rochester CTSA Career Development award (NIH-NCATS KL2TR000095, DSA, Bethesda, MD, USA) and National Institutes of Health (5U01NS090405-03, DSA, HL-33843, AJM; HL-51618, AJM; & HL-123483, AJM, Bethesda, MD, USA.) All authors have read and agree to the journals authorship agreement and policy on disclosure of potential conflicts of interest. None of the authors have any conflicts of interest pertinent to the content of the manuscript.

References

1. Kass RS, Moss AJ. Long QT syndrome: novel insights into the mechanisms of cardiac arrhythmias. *J Clin Invest.* 2003; 112:810–815. [PubMed: 12975462]
2. Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Priori SG, Benhorin J, Locati EH, Towbin JA, Keating MT, Lehmann MH, Hall WJ. Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. *N Engl J Med.* 1998; 339:960–965. [PubMed: 9753711]
3. Goldenberg I, Zareba W, Moss AJ. Long QT Syndrome. *Curr Probl Cardiol.* 2008; 33:629–694. [PubMed: 18835466]
4. James CA, Hadley DW, Holtzman NA, Winkelstein JA. How does the mode of inheritance of a genetic condition influence families? A study of guilt, blame, stigma, and understanding of inheritance and reproductive risks in families with X-linked and autosomal recessive diseases. *Genet Med.* 2006; 8:234–242. [PubMed: 16617244]
5. James CA, Tichnell C, Murray B, Daly A, Sears SF, Calkins H. General and disease-specific psychosocial adjustment in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy with implantable cardioverter defibrillators: a large cohort study. *Circ Cardiovasc Genet.* 2012; 5:18–24. [PubMed: 22238189]
6. Wesolowska K, Elovainio M, Koponen M, Tuiskula AM, Hintsanen M, Keltikangas-Jarvinen L, Maattanen I, Swan H, Hintsala T. Is Symptomatic Long QT Syndrome Associated with Depression in Women and Men? *J Genet Couns.* 2017; 26:491–500. [PubMed: 27553078]
7. Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Erb JL, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH. QT interval and antidepressant use: a cross sectional study of electronic health records. *Bmj.* 2013; 346:f288. [PubMed: 23360890]
8. Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, Huffman JC. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. *J Clin Psychiatry.* 2014; 75:e441–449. [PubMed: 24922496]
9. Waring WS. Clinical use of antidepressant therapy and associated cardiovascular risk. *Drug Healthc Patient Saf.* 2012; 4:93–101. [PubMed: 22936860]
10. Frommeyer G, Eckardt L. Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms. *Nat Rev Cardiol.* 2016; 13:36–47. [PubMed: 26194552]
11. Vieweg WV, Hasnain M, Howland RH, Hettema JM, Kogut C, Wood MA, Pandurangi AK. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? *Am J Med.* 2012; 125:859–868. [PubMed: 22748401]
12. Hasnain M, Vieweg WV. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. *CNS Drugs.* 2014; 28:887–920. [PubMed: 25168784]
13. Weeke P, Jensen A, Folke F, Gislason GH, Olesen JB, Andersson C, Fosbol EL, Larsen JK, Lippert FK, Nielsen SL, Gerds T, Andersen PK, Kanter JK, Poulsen HE, Pehrson S, Kober L, Torp-Pedersen C. Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. *Clin Pharmacol Ther.* 2012; 92:72–79. [PubMed: 22588605]
14. Leonard CE, Bilker WB, Newcomb C, Kimmel SE, Hennessy S. Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. *Pharmacoepidemiol Drug Saf.* 2011; 20:903–913. [PubMed: 21796718]
15. Czaja AS, Valuck RJ, Anderson HD. Comparative safety of selective serotonin reuptake inhibitors among pediatric users with respect to adverse cardiac events. *Pharmacoepidemiol Drug Saf.* 2013; 22:607–614. [PubMed: 23456956]

16. Zivin K, Pfeiffer PN, Bohnert AS, Ganoczy D, Blow FC, Nallamothu BK, Kales HC. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. *Am J Psychiatry*. 2013; 170:642–650. [PubMed: 23640689]
17. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. High-Dose Citalopram and Escitalopram and the Risk of Out-of-Hospital Death. *J Clin Psychiatry*. 2016
18. Qirjazi E, McArthur E, Nash DM, Dixon SN, Weir MA, Vasudev A, Jandoc R, Gula LJ, Oliver MJ, Wald R, Garg AX. Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study. *PLoS One*. 2016; 11:e0160768. [PubMed: 27513855]
19. Goldenberg I, Moss AJ. Long QT syndrome. *J Am Coll Cardiol*. 2008; 51:2291–2300. [PubMed: 18549912]
20. Woosley, R., Heise, C., Romero, K. QTdrugs List. AZCERT, Inc; 1822 Innovation Park Dr., Oro Valley, AZ 85755; Sep 25. 2017 www.CredibleMeds.org
21. CredibleMeds process for evaluating evidence and assigning risk. Sep 25. 2017 <https://www.crediblemeds.org/research-scientists/why-lists/>
22. Andersen PK, Gill RD. Cox's Regression Model for Counting Processes: A Large Sample Study. *The Annals of Statistics*. 1982; 10:1100–1120.
23. Danielsson B, Collin J, Jonasdottir Bergman G, Borg N, Salmi P, Fastbom J. Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study. *Br J Clin Pharmacol*. 2016; 81:773–783. [PubMed: 26574175]
24. Bird ST, Crensil V, Temple R, Pinheiro S, Demczar D, Stone M. Cardiac safety concerns remain for citalopram at dosages above 40 mg/day. *Am J Psychiatry*. 2014; 171:17–19. [PubMed: 24399423]
25. van Noord C, Sturkenboom MC, Straus SM, Witteman JC, Stricker BH. Non-cardiovascular drugs that inhibit hERG-encoded potassium channels and risk of sudden cardiac death. *Heart*. 2011; 97:215–220. [PubMed: 20406763]
26. Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. *Curr Drug Saf*. 2010; 5:97–104. [PubMed: 20210726]
27. Vieweg WV, Wood MA. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. *Psychosomatics*. 2004; 45:371–377. [PubMed: 15345781]
28. Yekehtaz H, Farokhnia M, Akhondzadeh S. Cardiovascular considerations in antidepressant therapy: an evidence-based review. *J Tehran Heart Cent*. 2013; 8:169–176. [PubMed: 26005484]
29. Licht CM, Penninx BW, de Geus EJ. Effects of antidepressants, but not psychopathology, on cardiac sympathetic control: a longitudinal study. *Neuropsychopharmacology*. 2012; 37:2487–2495. [PubMed: 22763618]
30. Perry M, Sanguinetti M, Mitcheson J. Revealing the structural basis of action of hERG potassium channel activators and blockers. *J Physiol*. 2010; 588:3157–3167. [PubMed: 20643767]
31. Milnes JT, Crociani O, Arcangeli A, Hancox JC, Witchel HJ. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. *Br J Pharmacol*. 2003; 139:887–898. [PubMed: 12839862]
32. Schwartz PJ. Another role for the sympathetic nervous system in the long QT syndrome? *J Cardiovasc Electrophysiol*. 2001; 12:500–502. [PubMed: 11332577]
33. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. *Circulation*. 2001; 103:89–95. [PubMed: 11136691]

Figure 1. Rate of recurrent CAEs when LQT1 and LQT2 patients were on ADs

Rate of recurrent CAEs (ACA, SCD, ventricular tachyarrhythmia, censored at 10 events) while on all ADs, SSRI ADs, ADs classified on the CredibleMeds List as Known Risk of TdP and Conditional (Cond.) Risk of TdP, and off all ADs. **A.** LQT1. **B.** LQT2. ADs: antidepressant drugs; CAEs: cardiac arrhythmic events; Cond: conditional; LQTS: Long QT Syndrome; SSRIs: selective serotonin reuptake inhibitor; TdP: Torsades de pointe; ACA: aborted cardiac arrest; SCD: sudden cardiac death.

Figure 2. LQT1 patients are at an increased risk of CAEs when on ADs

Hazard ratios of recurrent CAEs associated with all ADs, SSRI ADs, ADs with known risk of TdP, and ADs with conditional risk of TdP. Patients off all ADs were used as the reference group. Models were stratified by sex, and adjusted for baseline QT_c duration and time-dependent beta blocker usage. ADs: antidepressant drugs; CAEs: cardiac arrhythmic events; Cond: conditional; HR: hazard ratio; LQTS: Long QT Syndrome; SSRIs: selective serotonin reuptake inhibitor; TdP: Torsades de pointe; ACA: aborted cardiac arrest; SCD: sudden cardiac death.

Table 1

Patient Characteristics

Characteristics	QT _c Prolongation			
	LQT1 (n=59)	LQT2 (n=72)	LQT1 vs. LQT2	
Male	9 (15%)	26 (36%)		0.007
Follow-up (years)	53±20	48±17		0.163
ADs use and time on ADs				
Overall ADs	59 (100%)	72 (100%)		1.000
Total time per patient on any ADs (years)	5.92±5.60	5.44±5.01		0.965
SSRIs	48 (81%)	53 (74%)		0.294
Total time per patient on SSRI (years)	5.00±4.98	3.28±3.61		0.065
ADs with conditional TdP risk	41 (69%)	38 (53%)		0.052
Total time per patient on ADs with conditional TdP risk (years)	3.02±4.05	2.47±4.46		0.146
ADs with possible TdP risk	5 (8%)	8 (11%)		0.616
Total time per patient on ADs with Possible TdP risk (years)	0.43±2.36	0.33±1.24		0.628
ADs with known TdP risk	21 (36%)	31 (43%)		0.385
Total time per patient on ADs with known TdP risk (years)	2.34±4.09	1.74±2.94		0.832
ADs not on the CredibleMeds list	10 (17%)	18 (25%)		0.263
Total time per patient on ADs not on the list (years)	0.76±2.31	1.14±2.82		0.279
Anti-arrhythmic Treatment				
Beta-blockers	50 (85%)	66 (92%)		0.216
Left cardiac sympathetic denervation	0	4 (6%)		0.127
Pacemaker	4 (7%)	19 (26%)		0.003
Implantable Cardiac Defibrillator	26 (44%)	43 (60%)		0.074
Electrocardiogram				
Age at baseline ECG (years)	36±20	29±16		0.048
RR (sec)	893±198	879±195		0.691
PR (sec)	161±27	149±25		0.015
QRS (sec)	82±14	85±21		0.355
QT _c (sec)	515±52	519±53		0.572
Number of patients with cardiac arrhythmic events (CAEs)				

Characteristics	QTc Prolongation			LQT1 vs. LQT2
	LQT1 (n=59)	LQT2 (n=72)		
Ventricular tachyarrhythmias	15 (25%)	36 (50%)		<i>0.004</i>
Aborted cardiac arrest (ACA)	6 (10%)	13 (18%)		0.202
Sudden cardiac death (SCD)	0	1 (1%)		1.000
CAEs (Ventricular tachyarrhythmias, ACA, or SCD)	15 (25%)	39 (54%)		<i><0.001</i>

Data are mean ± SD for continuous variables and number of patients (%) for categorical variables. ADs: antidepressant drugs; CAEs: cardiac arrhythmic events; LQTS: Long QT Syndrome; SSRIs: selective serotonin reuptake inhibitor; TdP: Torsades de pointe; ACA: aborted cardiac arrest; SCD: sudden cardiac death.